Baxter (BAX) Misses Q4 EPS by 6c, Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Baxter Reports Fourth-Quarter and Full-Year 2022 Results
February 9, 2023 7:15 AM ESTFourth-quarter sales of $3.9 billion increased 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) of $0.36 and adjusted diluted EPS of $0.88 Full-year sales of $15.1 billion increased 18% on a reported basis, 23% on a constant currency basis and 2% on an operational basis Full-year U.S. GAAP diluted EPS (loss) of ($4.83) and adjusted diluted EPS of $3.50 Company provides update on previously announced actions to improve operational efficiency through streamlined operating model while positioning for proposed spinoff of Renal Care and Acute... More
